Multiple System Atrophy (MSA): Competitive Landscape

Multiple System Atrophy (MSA): Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Multiple System Atrophy therapeutics.

In 2024, more than 226,000 diagnosed prevalent cases of MSA are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast.

Currently, there is only one approved therapy available on the market for MSA.

The MSA pipeline holds 41 molecules, with no assets in the pre-registration stage or Phase III development. There are 10 assets in Phase II development.

Over the past 10 years, 60 clinical trials have been conducted in MSA. The highest number of studies were initiated in 2019 and 2023 (eight trials each).

During the past decade, licensing agreements were the most frequent type of deal in North America and Europe.

Scope

GlobalData’s Multiple System Atrophy: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Multiple System Atrophy market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Multiple System Atrophy market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.